PER-048-14已完成未知
A RANDOMIZED, DOUBLE-BLIND, DOUBLE DUMMY, COMPARATIVE, MULTICENTER STUDY TO ASSESS THE INCIDENCE OF HEMOLYSIS, SAFETY, AND EFFICACY OF TAFENOQUINE (SB-252263, WR238605) VERSUS PRIMAQUINE IN THE TREATMENT OF SUBJECTS WITH PLASMODIUM VIVAX MALARIA
GlaxoSmithKline,0 个研究点目标入组 100 人开始时间: 2014年11月13日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 16 至 100（—）
入选标准
- •1 A female is eligible to enter and participate in the study if she is non-pregnant, non-lactating and if she is of:
- •a. Non-childbearing potential defined as: post-menopausal (12 months of spontaneous amenorrhea or <6 months of spontaneous amenorrhea with serum FSH >40 mIU/mL), or pre-menopausal and has had a hysterectomy or a bilateral oophorectomy (removal of the ovaries) or a bilateral tubal ligation, negative pregnancy test or,
- •b. Child-bearing potential, has a negative pregnancy test at screening, and agrees to comply with one of the following during the treatment stage of the study and for a period of 90 days after stopping study medication
- •2.The subject has a glucose 6-phosphate dehydrogenase (G6PD) value (measured by a quantitative spectrophotometric phenotype assay) as follows:
- •Female subjects must have an enzyme level ≥40% of the site median value for G6PD normal males.
- •Male subjects must have an enzyme level ≥70% of the site median value for G6PD normal males.
- •3. The subject has a screening hemoglobin (Hb) value as follows:
- •Any subject with a G6PD value ≥70% of the site median value must have a screening Hb value ≥7 g/dL.
- •Female subjects with a G6PD value is ≥40% - <70% of the site median value must have a screening Hb value ≥8 g/dL
- •4.The subject has a QTcF of <450 msec
- •N.B. Reading based on an average of triplicate ECGs obtained over a brief recording period by machine or manual over-read
- •5.The subject has a positive malarial smear for P. vivax
排除标准
- •1. The subject has a mixed malaria infection (identified by a malarial smear or rapid diagnostic test).
- •2. The subject has severe P. vivax malaria as defined by WHO criteria.
- •3. The subject has a history of allergy to chloroquine, mefloquine, tafenoquine, primaquine, or to any other 4- or 8-aminoquinoline
- •4. The subject has a liver ALT >2 x ULN.
- •5. The subject has severe vomiting (no food or inability to take food during the previous 8 hours).
- •6. The subject has a clinically significant concurrent illness (e.g., pneumonia, septicemia), pre-existing condition (e.g., renal disease, malignancy), condition that may affect absorption of study medication (e.g., vomiting, severe diarrhea), or clinical signs and symptoms of severe cardiovascular disease (e.g., uncontrolled congestive heart failure, severe coronary artery disease).
- •7. The subject has a history of porphyria, psoriasis, or epilepsy.
- •8. The subject has a history of significant ocular disease (e.g. surgery to the globe, glaucoma, diabetic retinopathy) or has evidence of corneal or retinal abnormalities identified in the clinical screening ophthalmologic examination.
研究者
相似试验
招募中
不适用
A RANDOMIZED, DOUBLE-BLIND, DOUBLE DUMMY, PARALLEL GROUP, MULTICENTER 24 TO 52 WEEK VARIABLE LENGTH STUDY TO ASSESS THE EFFICACY AND SAFETY OF BUDESONIDE, GLYCOPYRRONIUM, AND FORMOTEROL FUMARATE METERED DOSE INHALER (MDI) RELATIVE TO BUDESONIDE AND FORMOTEROL FUMARATE MDI AND SYMBICORT®PRESSURIZED MDI IN ADULT AND ADOLESCENT PARTICIPANTS WITH INADEQUATELY CONTROLLED ASTHMA (KALOS)-J459 Asthma, unspecifiedAsthma, unspecifiedJ459PER-096-20AstraZeneca AB,
未知
不适用
A RANDOMIZED, DOUBLED-BLIND, DOUBLE-DUMMY, PLACEBO CONTROLLED MULTI-CENTRE STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FLUTICASONE FUROATE INHALATION POWDER AND FLUTICASONE PROPIONATE INHAATION POWDER IN THE TREATMENT OF ASTHMA IN ADULTS AND ADOLESCENTS NOT CURRENTLY TREATED WITH INHALED CORTICOSTEROIDSPER-076-11GLAXOSMITHKLINE PERU S.A.,119
未知
不适用
A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO CONTROLLED, MULTICENTER STUDY OF SUBCUTANEOUS SECUKINUMAB TO DEMONSTRATE EFFICACY AFTER TWELVE WEEKS OF TREATMENT, COMPARED PLACEBO AND ETANERCEPT AND TO ASSESS THE SAFETY, TOLERABILITY AND LONG-TERM EFFICACY UP TO ONE YEAR IN SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE-TYPE PSORIASISPER-054-11OVARTIS BIOSCIENSES PERU S.A.,
已完成
不适用
STUDY OF EFFICACY AND SAFETY OF OFATUMUMAB COMPARED TO TERIFLUNOMIDE IN PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS.-G35 Multiple sclerosisG35Multiple sclerosisPER-049-16OVARTIS BIOSCIENSES PERU S.A.,8
未知
不适用
A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OCRELIZUMAB IN COMPARISON TO INTERFERON BETA-1A (REBIF®) IN PATIENTS WITH RELAPSING MULTIPLE SCLEROSISPER-128-11F. Hoffmann La Roche Ltd / Genentech Inc,22